CTI BioPharma Corp (CTIC)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

3101 WESTERN AVENUE SEATTLE, WA 98121

Cell Therapeut develops, acquires and commercializes novel treatments for cancer. It markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia, or APL, in the U.S. and the European Union.

Data as of 2020-11-22
Market Cap273.619 Million Shares Outstanding73.752 Million Avg 30-day Volume785.477 Thousand
P/E Ratio-5.5 Dividend Yield EPS-0.68
Price/Sales Price cash flow ratio Price free cash flow ratio-6.4
Book Value0.63 Price to Tangible Book5.84 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.021919
BETA0.89969 52-week High/Low3.88 / 0.62 Stddev0.256085
View SEC Filings from CTIC instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 1 100.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 38 43 -11.63% 14 (0.92%) 15 (0.97%) -6.67%
13F shares: 39.584 Million 34.462 Million 14.86% 24.101 Million 23.371 Million 3.12%
% Ownership 53.6969 46.7716 14.81% 32.6942 31.7193 3.07%
New Positions: 5 8 -37.5% 2 3 -33.33%
Increased Positions 10 9 11.11% 3 3 0.0%
Closed Positions 10 3 233.33% 3 2 50.0%
Reduced Positions 8 10 -20.0% 2 3 -33.33%
Total Calls 250.618 Thousand 22.177 Thousand 1030.08% 42.5 Thousand
Total Puts 52.151 Thousand 0
PUT/CALL Ratio 0.21 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CTIC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CTIC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SEELEY BRUCE J. EVP, CHIEF OPERATING OFFICER

  • Officer
32,500 2020-06-30 2

TUCKSON REED VAUGHN

  • Director
0 2020-03-11 1

METZGER MICHAEL A

  • Director
0 2020-03-11 1

CRAIG ADAM R PRESIDENT AND CEO

  • Officer
  • Director
0 2020-03-11 1

PARKINSON DAVID ROSS

  • Director
0 2020-03-11 1

FISCHER LAURENT

  • Director
0 2020-03-11 1

KIRSKE DAVID EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2020-03-11 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • 10% Owner
9,520,000 2020-03-06 1

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
6,929,690 2020-03-02 1

BVF GP HOLDINGS LLC

BVF I GP LLC

BVF II GP LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
5,150,400 2020-03-02 1

PERRY MATTHEW D

  • Director
  • SEE EXPLANATION OF RESPONSES
43,139 2019-05-16 0

TELLING FRED

  • Director
0 2018-09-18 0

SINGER JACK W EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
0 2018-05-16 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
1,779,290 2018-02-08 0

LOVE RICHARD L

  • Director
73,718 2017-09-28 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

ISALY SAMUEL D

  • 10% Owner
5,000,000 2017-06-13 0

NUDELMAN PHILLIP M PHD

  • Director
73,129 2017-04-29 0

PLUNKETT MATTHEW EVP, CHIEF BUSINESS OFFICER

  • Officer
  • Director
0 2017-03-01 0

BIANCO JAMES A

  • Director
0 2016-10-02 0

MUNDINGER MARY ONEIL

  • Director
360,019 2016-04-29 0

BIANCO LOUIS A EVP, FINANCE & ADMINISTRATION

  • Officer
622,970 2016-03-21 0

BAUER JOHN H

  • Director
0 2015-09-23 0

IGNAGNI KAREN

  • Director
0 2015-09-23 0

BAXTER HEALTHCARE SA

  • 10% Owner
No longer subject to file 2015-04-30 0

GREGORIAN VARTAN

  • Director
468,937 2014-03-28 0

BAXTER HEALTHCARE SA

BAXTER INTERNATIONAL INC

  • 10% Owner
15,673,981 2013-11-25 0

BENNER STEVEN E EVP, CHIEF MEDICAL OFFICER

  • Officer
396,705 2013-03-21 0

PHILIPS CRAIG

  • FORMER PRESIDENT
414 2012-11-19 0

ERAMIAN DANIEL G EVP, CORPORATE COMMUNICATIONS

  • Officer
354,350 2012-09-20 0

STROMATT SCOTT EVP,CLINICAL DEV & REG AFFAIR

  • Officer
No longer subject to file 2008-04-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments